DHL Group said this week it is investing $2 billion through 2030 to grow its life sciences and healthcare logistics business, with $860 million going to North America.
The company announced the plan on Monday, saying the money will go toward expanding cold storage, building new pharma hubs, and adding more temperature-controlled vehicles to support sensitive medical shipments like clinical trials, vaccines, and gene therapies.
“Similar to DHL Group’s purpose of ‘Connecting people, improving lives,’ our strategic investment in life sciences and healthcare is driven by our customers’ mission: delivering essential, often life-saving products to people in need,” said Oscar de Bok, CEO of DHL Supply Chain. “We’re building high-quality, integrated logistics solutions that are as innovative and reliable as the products our customers create — ensuring that patients everywhere receive the right treatment, at the right time, with complete confidence.”
Please click here to read the complete article.
